Evolution Advisers’s Globus Medical GMED Stock Holding History

Evolution Advisers’s Portfolio GMED Stock Details GMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Buy	+2	New	+$170	﹤0.01%	480

Other funds holding GMED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Evolution Advisers's GMED Position: Q2 2026 in Review

Evolution Advisers opened a new position in Globus Medical (GMED) in Q2 2026: 2 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #480 among its holdings.

594 funds tracked by Wall St. Rank hold GMED as of Q2 2026.

Evolution Advisers held 2 shares of Globus Medical worth $0 as of Q2 2026.
Globus Medical was a new Evolution Advisers position in Q2 2026.
Globus Medical made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #480 holding.
594 funds tracked by Wall St. Rank held Globus Medical as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.